Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP

Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-associated protein (FRAP). A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resolution of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously. The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins. The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects observed for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasia mutant gene product, and it illustrates how a small cell-permeable molecule can mediate protein dimerization.

[1]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.

[2]  S. Schreiber,et al.  Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[4]  S. Schreiber,et al.  Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.

[5]  V. Zakian.  ATM-related genes: What do they tell us about functions of the human gene? , 1995, Cell.

[6]  P. Caron,et al.  X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex , 1995, Cell.

[7]  S. Schreiber,et al.  Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.

[8]  F. Lederer,et al.  Improvement of the 2.5 A resolution model of cytochrome b562 by redetermining the primary structure and using molecular graphics. , 1979, Journal of molecular biology.

[9]  Nolan H. Sigal,et al.  A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.

[10]  R F Standaert,et al.  Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex , 1991, Science.

[11]  S. Schreiber,et al.  Controlling signal transduction with synthetic ligands. , 1993, Science.

[12]  S. Schreiber,et al.  Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Stuart L. Schreiber,et al.  TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin , 1995, Cell.

[14]  Masashi Hashimoto,et al.  Structure of FK506, a novel immunosuppressant isolated from Streptomyces , 1987 .

[15]  Mike Carson,et al.  Ribbon models of macromolecules , 1987 .

[16]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[17]  T. Hunter,et al.  When is a lipid kinase not a lipid kinase? When it is a protein kinase , 1995, Cell.

[18]  S. Schreiber,et al.  PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints , 1995, Science.

[19]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[20]  N L Harris,et al.  Four helix bundle diversity in globular proteins. , 1994, Journal of molecular biology.

[21]  The X-ray crystal structure of rapamycin, C51H79NO13 , 1978 .

[22]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[23]  R F Standaert,et al.  Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. , 1993, Journal of molecular biology.

[24]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[25]  J. Heitman,et al.  TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin (*) , 1995, The Journal of Biological Chemistry.

[26]  Anna Tempczyk,et al.  Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.

[27]  J. Findlay,et al.  On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin , 1980 .

[28]  Stuart L. Schreiber,et al.  Atomic Structure of the Rapamycin Human Immunophilin FKBP-12 Complex , 1991 .

[29]  S. Schreiber,et al.  A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.

[30]  S. P. Jackson,et al.  Cancer Predisposition: Ataxia–telangiectasia at the crossroads , 1995, Current Biology.

[31]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.